SCHEMBL443826

SCHEMBL443826

CC(=O)c1cc(Cl)nc(NN)c1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.37
CA5A P35218 1/20 0.36
S1PR2 O95136 1/20 0.36
AHR P35869 1/20 0.36
LMNA P02545 1/20 0.35
KDM4E B2RXH2 3/20 0.34
GAA P10253 3/20 0.34
ADORA3 P0DMS8 3/20 0.33
MAPT P10636 2/20 0.33
GRM5 P41594 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
PKM P14618 1/20 0.33
KMT2A Q03164 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476639 0.84 ALDH1A1 (0.43) ALDH1A1S1PR2KDM4EGAAMAPT
SCHEMBL219689 0.82 KDM4E (0.49) ALDH1A1S1PR2LMNAKDM4EGAA
SCHEMBL362611 0.80 CA5A (0.48) ALDH1A1CA5AS1PR2AHRLMNA
SCHEMBL30612226 0.78 STAT3 (0.38) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL454489 0.78 STAT3 (0.38) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL6251916 0.76 CA5A (0.40) ALDH1A1CA5AS1PR2AHRLMNA
SCHEMBL19690901 0.73 EGFR (0.46) ALDH1A1S1PR2LMNAKDM4EGAA
SCHEMBL29561847 0.73 SMN1; SMN2 (0.46) ALDH1A1CA5AS1PR2LMNAKMT2A
SCHEMBL4928556 0.73 SMN1; SMN2 (0.46) ALDH1A1CA5AS1PR2LMNAKMT2A
SCHEMBL5761347 0.73 ALDH1A1 (0.52) ALDH1A1CA5ALMNAKDM4ETAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 ALDH1A1 2538/4885CA5A 3490/4885S1PR2 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.